Clinical Trial Update: A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study in pediatric Type 2 diabetes participants evaluating MK-0431A XR tablets' swallowability and exposure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MK-0431A XR

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2015-05-22